We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy.
- Authors
Gastinne, Thomas; Le Bourgeois, Amandine; Coste‐Burel, Marianne; Guillaume, Thierry; Peterlin, Pierre; Garnier, Alice; Imbert, Berthe‐Marie; Drumel, Thomas; Mahe, Beatrice; Dubruille, Viviane; Blin, Nicolas; Lok, Anne; Touzeau, Cyrille; Tessoulin, Benoit; Jullien, Maxime; Vanthygem, Sophie; Béné, Marie C.; Moreau, Philippe; Le Gouill, Steven; Chevallier, Patrice
- Abstract
All except two patients were in complete remission at the time of first vaccine, while three patients were still on therapy (revlimid I n i = 1, tafasitamab I n i = 1, chemotherapy I n i = 1). Keywords: COVID 19; vaccine; CAR-T cells; BNT162b2; SARS-CoV-2 mRNA EN COVID 19 vaccine CAR-T cells BNT162b2 SARS-CoV-2 mRNA 360 362 3 01/17/22 20220115 NES 220115 The efficacy of anti-SARS-CoV-2 messenger RNA vaccines was first demonstrated in healthy populations.1 It was later progressively reported in immunocompromised hosts, including patients with solid tumours,2 haematological malignancies, especially B-cell chronic lymphocytic leukaemia,3,4 as well as solid organ transplants.5,6 Surprisingly, the antibody response has been shown to be impressive (around 80%) only in recipients of allogeneic haematopoietic stem cells transplant.7-9 Another immunocompromised population is patients who have received chimeric antigen receptor-T (CAR T) cell therapy. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
- Subjects
CHIMERIC antigen receptors; CHRONIC leukemia; ANTIBODY formation; COVID-19 vaccines
- Publication
British Journal of Haematology, 2022, Vol 196, Issue 2, p360
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17818